Kennedy Capital Management LLC Acquires 20,635 Shares of Boston Scientific Co. (NYSE:BSX)

Kennedy Capital Management LLC boosted its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 26.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 99,515 shares of the medical equipment provider's stock after buying an additional 20,635 shares during the period. Kennedy Capital Management LLC's holdings in Boston Scientific were worth $8,889,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in BSX. Treasurer of the State of North Carolina grew its holdings in Boston Scientific by 0.4% in the fourth quarter. Treasurer of the State of North Carolina now owns 665,490 shares of the medical equipment provider's stock worth $59,442,000 after purchasing an additional 2,560 shares during the last quarter. Legacy Financial Advisors Inc. grew its stake in shares of Boston Scientific by 33.8% during the 4th quarter. Legacy Financial Advisors Inc. now owns 5,320 shares of the medical equipment provider's stock worth $475,000 after purchasing an additional 1,343 shares during the period. CenterBook Partners LP acquired a new position in shares of Boston Scientific in the fourth quarter worth about $1,144,000. DRW Securities LLC purchased a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $233,000. Finally, APG Asset Management N.V. raised its holdings in shares of Boston Scientific by 404.2% during the fourth quarter. APG Asset Management N.V. now owns 1,021,217 shares of the medical equipment provider's stock valued at $88,088,000 after acquiring an additional 818,675 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

Shares of NYSE BSX traded up $1.49 during midday trading on Wednesday, reaching $95.72. The company's stock had a trading volume of 3,375,971 shares, compared to its average volume of 6,352,338. The company has a market cap of $141.58 billion, a P/E ratio of 76.58, a P/E/G ratio of 2.79 and a beta of 0.73. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. Boston Scientific Co. has a fifty-two week low of $66.80 and a fifty-two week high of $107.17. The business's 50 day moving average price is $100.11 and its two-hundred day moving average price is $94.18.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Argus set a $130.00 target price on shares of Boston Scientific in a report on Tuesday, February 18th. Piper Sandler increased their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Wells Fargo & Company lifted their price target on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Raymond James boosted their price target on Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research report on Thursday, February 6th. Finally, Morgan Stanley raised their price objective on shares of Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. One equities research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $110.22.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the transaction, the executive vice president now directly owns 5,502 shares in the company, valued at approximately $560,103.60. This represents a 75.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the sale, the executive vice president now directly owns 28,454 shares of the company's stock, valued at $2,966,329.50. This trade represents a 14.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 133,183 shares of company stock worth $13,948,476 in the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.